Evidence map›Paper›PMID 32457152›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

In vivo mapping of a GPCR interactome using knockin mice.

Jade Degrandmaison, Khaled Abdallah, Véronique Blais, Samuel Génier, Marie-Pier Lalumière, Francis Bergeron, Catherine M Cahill, Jim Boulter, Christine L Lavoie, Jean-Luc Parent and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Jade DegrandmaisonDépartement de Médecine, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Khaled AbdallahDépartement de Pharmacologie-Physiologie, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Véronique BlaisDépartement de Pharmacologie-Physiologie, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Samuel GénierDépartement de Médecine, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Marie-Pier LalumièreDépartement de Médecine, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Francis BergeronDépartement de Pharmacologie-Physiologie, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Catherine M CahillDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA 90095.
Jim BoulterDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA 90095.
Christine L LavoieDépartement de Pharmacologie-Physiologie, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.ORCID 0000-0002-7673-5834
Jean-Luc ParentDépartement de Médecine, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada; jean-luc.parent@usherbrooke.ca louis.gendron@usherbrooke.ca.
Louis GendronDépartement de Pharmacologie-Physiologie, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada; jean-luc.parent@usherbrooke.ca louis.gendron@usherbrooke.ca.ORCID 0000-0002-2058-8863
Université de Sherbrooke · CAUniversity of California, Los Angeles · US

Funding

CIHR MOP-136871CIHR PJT-162103
6 · The paper itself

Abstract

With over 30% of current medications targeting this family of proteins, G-protein-coupled receptors (GPCRs) remain invaluable therapeutic targets. However, due to their unique physicochemical properties, their low abundance, and the lack of highly specific antibodies, GPCRs are still challenging to study in vivo. To overcome these limitations, we combined here transgenic mouse models and proteomic analyses in order to resolve the interactome of the δ-opioid receptor (DOPr) in its native in vivo environment. Given its analgesic properties and milder undesired effects than most clinically prescribed opioids, DOPr is a promising alternative therapeutic target for chronic pain management. However, the molecular and cellular mechanisms regulating its signaling and trafficking remain poorly characterized. We thus performed liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses on brain homogenates of our newly generated knockin mouse expressing a FLAG-tagged version of DOPr and revealed several endogenous DOPr interactors involved in protein folding, trafficking, and signal transduction. The interactions with a few identified partners such as VPS41, ARF6, Rabaptin-5, and Rab10 were validated. We report an approach to characterize in vivo interacting proteins of GPCRs, the largest family of membrane receptors with crucial implications in virtually all physiological systems.

Indexed as

AnimalsBrainChromatography, High Pressure LiquidFemaleGene Knock-In TechniquesGenes, ReporterMaleMiceMice, TransgenicProtein FoldingProtein Interaction MappingProtein Interaction MapsProteomicsReceptors, Opioid, deltaSignal TransductionTandem Mass SpectrometryDOR-1 protein, mouseReceptors, Opioid, deltaGPCR interactomeG-protein–coupled receptorsmass spectrometrymouse modelδ-opioid receptor

Identifiers

PMID32457152
PMCPMC7293596
OpenAlexW3031076834

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.